I hope your 2023 is off to a great start! As we begin a new year, the Absolute Antibody team is looking forward to tackling new antibody engineering challenges and taking on new opportunities as part of our new parent company Absolute Biotech.

“I hope your 2023 is off to a great start! As we begin a new year, the Absolute Antibody team is looking forward to tackling new antibody engineering challenges and taking on new opportunities as part of our new parent company Absolute Biotech. Check out some of our latest updates below and be sure to reach out to discuss your own antibody projects.”

- Dr. Michael Fiebig, Chief Scientific Officer

Comparing Potential Bispecific Formats

Multispecific antibodies with varying designs continue to enter the clinic, with a recent report stating that 79 multispecific antibodies encompassing 25 different designs are now clinically available. But not every antibody can be combined to produce well-behaved multispecifics. The valency and geometry of each design can determine the production, target engagement and ultimately the requisite biological functions.

In a new case study led by our Head of Protein Engineering Dr. Donmienne Leung, we selected two established antibody therapeutics, trastuzumab and a humanized OKT3, to produce 17 different bispecific formats to compare the feasibility of each format. Download our research poster to learn more >

Humanized Antibodies from Different Origin Species

Looking for more from our Head of Protein Engineering? Check out this brief online presentation in which Dr. Donmienne Leung describes our Prometheus™ 2.0 Antibody Humanization Service, which can provide humanized antibodies from mouse, rat, rabbit, and camelid origin. The service is uniquely focused on delivering humanized antibodies with robust manufacturability, enabling the

optimized large-scale production required for clinical use. Watch the presentation here, or download our humanization research poster for more details.

New Paper Illustrates Benefits of Syngeneic Antibodies

A recent paper, published in Cells by researchers at University Medical Center Utrecht in the Netherlands, showed that our VivopureX™ mouse-anti-mouse Ly-6G antibody was able to deplete neutrophils in mice more efficiently than the original rat Ly-6G antibody. The paper demonstrated how using a mouse IgG2a version of the antibody increased depleting effector function, and prevented the production of anti-rat antibodies, highlighting the importance of using recombinantly produced syngeneic antibodies tailored to the specific research questions in vivo. Read the paper here, and learn more about our VivopureX™ line of species-matched engineered recombinant antibodies here.

Recombinant Engineered Virus Antibodies

We’ve recently been focused on expanding and validating our collection of recombinant engineered antibodies against key infectious diseases. Check out our features on antibodies against the following viruses that impact human health: influenza A (ELISA data to the left), cytomegalovirus, norovirus, monkeypox and RSV. All antibody clones are available off-the-shelf in different species, isotypes and formats, with custom engineering available upon request.

Upcoming Conferences

We have a busy event schedule planned for 2023, filled with our regular shows as well as new (and new to us!) conferences. Up next are the European Multispecific Antibody Congress in Amsterdam, Biologics UK in London, and AACR and PEGS Boston in the USA. If you’re planning to attend, contact us to schedule a meeting.

Absolute Biotech’s Cancer Research Reagents

In case you missed the announcement in the fall, Absolute Antibody is now part of Absolute Biotech, a new company that unites multiple life science brands into one organization specializing in antibody reagents and services. While it is still very much business as usual for our customers and partners, we’re excited to begin introducing you to the combined Absolute Biotech portfolio. For a sneak peek, check out a new flier highlighting cancer research reagents from all our sister companies.

Thanks for reading! If you’d like to receive more regular updates, be sure to follow us on LinkedIn and Twitter.

This message was sent to user@example.com from:

Absolute Antibody | news@absantibody.com | Absolute Antibody NA | 2 Shaker Road, Unit B101 | Shirley, MA 01464

Unsubscribe